About
CanDapi develops and produces a new type of innovative single dose for multi-use Dry Powder Inhaler (DPI) platform for delivering medications, including cannabinoids to the lungs in the form of a dry powder for various treatments. In addition, CanDapi develops a new line of delivery platforms to the lungs and nose for capsuled drugs in powder or liquid forms Our Solution - A new method of medicine inhalation, developed by CanDapi, in the form of totally new patented inhalers. - The new CanDapi DPI is operated using high-frequency vibrations activated by inhaling. This method is an exceptional and innovative drug delivery mechanism with tested results of over 85% efficiency by Kiel University, Germany, and efficiency of medical CBD powder of 92% as tested by Cannasoul Analytics (The Technion company). - The most effective platform for new drugs including biopharmaceutics. - The safest and most effective platform suitable for the efficient delivery of cannabinoid powder ingredients. - The perfect solution for more effective treatment for lung diseases such as asthma and COPD (Chronic Obstructive Pulmonary Disease).
Technologies
Keywords
Company Information
-
Employees 2
-
Founded 2022
Location
Yeruham, South District, Israel, 80500
